Valiant Organics Ltd Q3 FY2024 Concall Summary

Key Takeaways

• A quarter defined by dumping and demand stress: Revenue fell 22% YoY as China’s dumping of import-substitute products collided with a European demand slowdown, compressing both volumes and prices.
• PAP: the promise is intact, the timeline is not: December’s surge to 370 metric tons signals a demand turnaround, but the earlier ₹300 cr revenue target is now ₹200–250 cr and the 5-year payback has extended.
• The margin reset is structural, not cyclical: EBITDA margins have compressed from 27% in FY21 to 8% in 9M FY24 because the company expanded into newer, margin-dilutive products while geopolitical turmoil hit the last two years.
• FY25 bets on a ~40% top-line jump: Management is targeting ₹900–1,000 cr revenue, contingent on Chinese domestic demand absorbing the inventory overhang and dumping abating.
• What to watch next quarter: Whether PAP volumes sustain above 600 tons/month as external customers are onboarded, any signal that Chinese dumping is easing, and the trajectory of chlorophenol pricing into Europe.

Demand & Pricing Environment

• China dumping is the central headwind: Chinese producers face reduced domestic demand, causing inventory buildup that is being dumped into global markets at significantly lower prices. Valiant’s portfolio is mostly import-substitute products, so this hits directly.
• Europe slowdown compounds the pain: The global slowdown, mainly in Europe, has suppressed demand across product categories. Management is watching for a structural decline in European chemicals but says it is too early to assess direct impact.
• Pricing pressure is broad-based: A 9% price reduction drove the revenue decline alongside the 13% volume drop. Margins corrected significantly even where chlorination volumes grew, because the company had to stay competitive against dumped Chinese supply.
• Raw material relief is partial: Raw material prices have come down with product price corrections, so contribution margins have remained more or less similar quarter-on-quarter, but absolute profitability is still compressed.
• The turnaround bet is unproven: Management believed the same thing last year and it did not materialize. The current view is that the situation is prolonged but temporary, and the company will wait another quarter before reassessing strategy.

Mihir Shah: “So next year, it is really difficult when we were sitting, at the same time last year we believed that things would turn around, but it actually hasn’t. So, it’s taking a lot longer and nobody really knows how quickly things will turn around.”

PAP: The Volume Story

• December surge offers a green shoot: PAP averaged only 119 metric tons per month in October–November due to subdued paracetamol demand, but December jumped to 370 metric tons, indicating a possible demand inflection.
• Capacity is no longer the bottleneck: Earlier technological issues moving from continuous to batch process reduced capacity, but reactor additions have restored the full 1,000 tons/month nameplate. The limiting factor is now customer acquisition.
• Customer concentration caps utilization: The primary buyer, Valiant Laboratories (now an associate at 46.83% stake), reaches maximum utilization at 600–650 tons/month. Onboarding external customers is in progress, with approvals underway and marketing ongoing.
• Revenue target cut by price, not volume: Full-capacity PAP revenue is now expected at ~₹200–250 cr, down from ~₹300 cr, because prices have corrected significantly. The 5-year payback period has extended accordingly.
• Purity is not the issue: Management confirmed purity levels have remained constant since last quarter; the volume drop is purely demand-driven, not a quality problem.

Mihir Shah: “We are hoping to scale to around 600, 700 metric tons by the year end. That is what we are expecting. I wouldn’t confirm or promise that but that is what we are looking towards.”

Product Portfolio & Capacity

• New products are the margin recovery engine: Management’s aim to return to upward of 20% EBITDA margin is not achievable with the existing product portfolio alone; it depends on new products, existing products and innovations over the next two years.
• Three new revenue streams identified: PAP at full capacity adds ~₹200 cr, Pharma Intermediates ~₹80 cr, and OAP ~₹20–30 cr, totaling ~₹300 cr incremental revenue. Existing product revenue is expected to stay constant as volume gains offset price corrections.
• Capacity built, waiting for demand: Excluding PAP, about 2,000 metric tons of annual capacity has been added across chlorophenol (~1,200 tons), ammonolysis (~6,000 tons per annum), and hydrogenation at Jhagadia (~500 tons).
• New chlorophenol products near launch: Final-stage development; expected to enter the portfolio in Q1 of next fiscal year. Revenue contribution cannot be estimated yet and will be assessed after market launch.
• Chlorination cost position is competitive: The company is towards the lowest end of the cost curve. Some Chinese players shut plants a couple of years ago, and one that relocated to Mongolia faces 3–4 months of annual shutdown from extreme temperatures.
• Ammonolysis weakened after a brief recovery: After a momentary turnaround in September, October–November volumes declined significantly from the previous quarter.

Mihir Shah: “the aim of being around 20% margin is arising out of our current new products, existing products and some innovations that we'll down the way right in next two years. So, all of that, our aim and goal remain to be upward of 20%, not with the existing product portfolio itself.”

Margins & Profitability

• The margin compression is multi-year: EBITDA margins fell from 27% in FY21 to 8% in 9M FY24. The decline reflects expansion into newer, margin-dilutive products (though absolute EBITDA increased) plus two years of geopolitical turmoil.
• Pricing pressure overrides volume gains: Margins corrected significantly in the quarter despite higher chlorination volumes, because demand was insufficient and the company had to price competitively against dumped Chinese supply.
• The 20% target is a FY26 story, not FY25: Management’s aim is to stay upward of 20% EBITDA margin, but FY25 is not when they will be in that range. Initial quarters may be weaker, with the second half stronger, and new products arriving by FY26 will drive the step-change.
• No inventory write-off needed currently: Management confirmed no current requirement to write off or rebase inventory in working capital, though a question about rebasing the working capital debt itself went unaddressed.

Competitive Landscape

• China is the only competitor for chlorophenols: Chinese dumping of chlorophenol is mostly directed at European markets and at Indian players who export to Europe, not directly into the Indian domestic market.
• Dumping shows no sign of easing: Management sees no indication of change in the dumping situation over the next few months and declined to predict how it will evolve, stating they are not in a position to make that call.
• The end-user mix is shifting: The breakup has been moving because chlorination was hit by a fire last year, reducing its contribution significantly; the company is now regaining that share as the market expands.
• No new end-user segments targeted: Management is optimistic that existing segments (agrochem, textiles, paracetamol, pharma intermediates) will turn around, and is not currently targeting new segments.

Mihir Shah: “Yes, it is definitely an issue, because we are mostly import substitute products and those imports are from China, and if China is dumping at a significantly lower price, then it does become a point of concern for us.”

Guidance & Commitments

Key Metrics